Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite gloomy skies that can be seen from our window. And why not? Keep on the sunny side, as they say. Moreover, our rambunctious official mascot is happily snoozing at our feet. A rare respite from the usual noisy friskiness, which is to say we can get more work done. In fact, here are a few tidbits to help your morning move along. Let us now raise a cup of stimulation to another interesting and productive day. And of course, do keep in touch. …

Most Americans have never heard of Dr. Richard Whitley, an expert in pediatric infectious diseases at the University of Alabama-Birmingham, but as the pandemic drags on and the public eagerly awaits a vaccine, he may well be among the most powerful people in the country, Kaiser Health News says. Whitley leads a small, secret panel of experts tasked with reviewing safety and effectiveness data of Covid-19 vaccines that U.S. taxpayers helped fund. The data and safety monitoring board also has the power to halt a clinical trial or fast-track it.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Forgive me for observing that Mr. Trumps comment – “an FDA decision to revise the standards, first issued in June, “was a political move more than anything else.” – is rather nakedly more political than the FDA’s decision.
    One may further observe that while Mr. Trump appears to see the greater good as that which benefits his reelection, one hopes the FDA will truly see it as that which benefits the pubic health of the American population. (Would that the CDC do the same?)

Comments are closed.